Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target...
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target...
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity...
EMERYVILLE, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology...
Shojaei brings over two and a half decades of experience in clinical pharmaceutical developmentBALTIMORE, Oct. 08, 2021 (GLOBE NEWSWIRE) --...
Oslo, October 8, 2021: Ultimovacs ASA today announced two senior appointments to its management team: Orla Mc Callion as Head...
Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red...
Denver, Colorado--(Newsfile Corp. - October 8, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a full-line CBD and hemp...
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2021) - CENTR Brands Corp. (CSE: CNTR) (FSE: 303) (OTCQB: CNTRF) today announced...
TORONTO--(BUSINESS WIRE)--$PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform...
Experts are warning that a severe influenza wave is on the way – especially given that many places have now...
INCLUDES NEW CELL TYPES FOR STUDYING MOLECULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASESTRIGGERS US$ 9.0 M...